CredoScientia - Bibliothèque

Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.

The combination therapy of Tislelizumab plus Lenvatinib has recently emerged as the new standard of care for unresectable hepatocellular carcinoma (HCC). This treatment has demonstrated a significant …

Thérapies de Conversion

Xie, Y., Lyu, T., Zou, Y., & Wang, J. (2024). Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.. Front Oncol, 14, 1369567. https://doi.org/10.3389/fonc.2024.1369567

01/01/2024 Lire →

Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review.

With the development of comprehensive treatment, locoregional transarterial chemotherapy has become an alternative conversion therapy, palliative therapy, and neoadjuvant therapy for many solid malign…

Thérapies de Conversion

Meng, W., Pan, L., Huang, L., Li, Q., & Sun, Y. (2024). Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review.. Front Oncol, 14, 1464242. https://doi.org/10.3389/fonc.2024.1464242

01/01/2024 Lire →

Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.

PURPOSE: Intra-arterial conversion therapy (ICT) is a promising option for patients with unresectable hepatocellular carcinoma (uHCC). However, the selection of sequential therapeutic modalities is st…

Thérapies de Conversion

Du, Y., An, C., & Liu, W. (2024). Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.. Int J Hyperthermia, 41(1), 2380001. https://doi.org/10.1080/02656736.2024.2380001

01/01/2024 Lire →

Comparison of immunochemotherapy and chemotherapy alone in conversion therapy for locally advanced unresectable esophageal squamous cell carcinoma.

BACKGROUND: The clinical value of preoperative immunochemotherapy and simple chemotherapy induction regimen in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinom…

Thérapies de Conversion

Xu, Z., You, Z., Chen, M., Zhang, M., Shen, C., Xu, D., Xu, K., & Tian, W. (2024). Comparison of immunochemotherapy and chemotherapy alone in conversion therapy for locally advanced unresectable esophageal squamous cell carcinoma.. Front Oncol, 14, 1370353. https://doi.org/10.3389/fonc.2024.1370353

01/01/2024 Lire →

Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.

Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy globally, with the majority of patients presenting at the initial diagnosis with locally advanced or metastatic disease, preclu…

Thérapies de Conversion

Ai, H., Gong, T., Ma, Y., Ma, G., Ding, W., Ding, W., Wang, W., & Zhao, X. (2024). Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.. Front Immunol, 15, 1358602. https://doi.org/10.3389/fimmu.2024.1358602

01/01/2024 Lire →

Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma.

Thérapies de Conversion

Fu, M. . M. . L., Jiang, M. . M. . J., Liu, M. . M. . M., Li, M. . M. . J., & Zhu, M. . D. . H. (2024). Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma.. Gastroenterol Nurs, 47(3), 222-228. https://doi.org/10.1097/SGA.0000000000000770

01/01/2024 Lire →

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.

PURPOSE: To explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM).PATIEN…

Thérapies de Conversion

Yang, W., Chen, D., Niu, Y., Wu, G., Huang, Z., Bi, X., Zhao, H., Che, X., & Sun, Y. (2024). FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.. Front Oncol, 14, 1375906. https://doi.org/10.3389/fonc.2024.1375906

01/01/2024 Lire →

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.

Hepatocellular carcinoma is a rather common malignant tumor. Most patients with hepatocellular carcinoma receive their diagnosis at an advanced stage, at which surgical resection is no longer appropri…

Thérapies de Conversion

Liu, X. L., Li, X. Z., Chu, Y. F., Liu, F., & Tian, H. (2024). Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.. Front Oncol, 14, 1280805. https://doi.org/10.3389/fonc.2024.1280805

01/01/2024 Lire →

"Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.

This is a mixed methods international survey of therapists ( = 89) belonging to Therapy First, an organization supporting the use of exploratory therapy, rather than gender affirmative therapy, with g…

Thérapies de Conversion

Jenkins, P., & Panozzo, D. (2024). "Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.. J Sex Marital Ther, 50(5), 557-582. https://doi.org/10.1080/0092623X.2024.2329761

01/01/2024 Lire →

Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.

BACKGROUND: LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced C with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-rel…

Thérapies de Conversion

Anft, M., Zgoura, P., Skrzypczyk, S., Dürr, M., Viebahn, R., Westhoff, T. H., Stervbo, U., & Babel, N. (2024). Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.. Front Transplant, 3, 1405070. https://doi.org/10.3389/frtra.2024.1405070

01/01/2024 Lire →

Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study.

PURPOSE: This study aimed to investigate the benefit of conversion therapy for patients with unresectable hepatocellular carcinoma (HCC).PATIENTS AND METHODS: A retrospective cohort study was conducte…

Thérapies de Conversion

Han, R., Gan, L., Sun, L., Lang, M., Tian, X., Zhu, K., Chen, L., Li, G., & Song, T. (2024). Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study.. J Hepatocell Carcinoma, 11, 1835-1844. https://doi.org/10.2147/JHC.S482803

01/01/2024 Lire →

Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.

BACKGROUND: This study aimed to assess the effect of adjuvant therapy with different durations in patients with initially unresectable hepatocellular carcinoma (uHCC) after conversion surgery.METHODS:…

Thérapies de Conversion

Lin, Z. T., Wei, S. M., Wu, J. Y., Zhang, Z. B., Wang, S. J., Zhou, J. Y., Luo, M. C., Zeng, Z. X., Ou, X. Y., Fu, Y. K., Li, H., Liu, D. Y., Wu, J. Y., & Yan, M. L. (2024). Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study.. J Hepatocell Carcinoma, 11, 1777-1787. https://doi.org/10.2147/JHC.S477019

01/01/2024 Lire →